Pan-cancer analysis revealed that compared to non-cancerous tissues, AKR1B10 expression was significantly elevated in cholangiocarcinoma (CHOL), hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate cancer (PRAD), and uterine endometrial cancer (UCEC). Here, AKR1B10 is linked to prostate cancer.